Reactivity of Platelia Aspergillus Galactomannan Antigen with Piperacillin-Tazobactam: Clinical Implications Based on Achievable Concentrations in Serum
Open Access
- 1 June 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (6) , 1989-1992
- https://doi.org/10.1128/aac.48.6.1989-1992.2004
Abstract
The possible reactivities of commonly used antibiotics of fungal, nonfungal, and nonmicrobial or synthetic sources with the Platelia Aspergillus galactomannan assay were assessed. For drugs that tested positive, the minimal concentration of the antibiotic in serum that yielded a positive test (index, >0.5) was determined. At undiluted concentrations, piperacillin and multiple lots of piperacillin-tazobactam tested positive, whereas amoxicillin, ampicillin-sulbactam, nafcillin, cefazolin, ceftazidime, erythromycin, gentamicin, and levofloxacin tested negative. All three lots of piperacillin-tazobactam and all bags within each lot tested positive, with a mean index value of 5.168. At achievable concentrations in serum, however, only one of three lots of piperacillin-tazobactam yielded a positive test. Concentrations of 75, 150, and 300 μg/ml of serum tested positive with the Platelia Aspergillus enzyme immunoassay, whereas lower concentrations, mimicking the trough levels, tested negative. Thus, while achievable serum piperacillin-tazobactam concentrations may potentially result in a positive test for galactomannan, the timing of the collection of serum samples from patients may influence the test results, with reactivity being less likely in samples collected at trough levels or prior to the administration of a dose of the antibiotic.Keywords
This publication has 16 references indexed in Scilit:
- Treatment with Piperacillin‐Tazobactam and False‐PositiveAspergillusGalactomannan Antigen Test Results for Patients with Hematological MalignanciesClinical Infectious Diseases, 2004
- False‐Positive Galactomannan PlateliaAspergillusTest Results for Patients Receiving Piperacillin‐TazobactamClinical Infectious Diseases, 2004
- Prospective Assessment of Platelia™Aspergillus Galactomannan Antigen for the Diagnosis of Invasive Aspergillosis in Lung Transplant RecipientsAmerican Journal of Transplantation, 2004
- Cold Ischemic Injury of Transplanted Organs: Some New Strategies Against an Old ProblemAmerican Journal of Transplantation, 2004
- Efficacy of Galactomannan Antigen in the Platelia Aspergillus Enzyme Immunoassay for Diagnosis of Invasive Aspergillosis in Liver Transplant RecipientsJournal of Clinical Microbiology, 2004
- False Positive Test for Aspergillus Antigenemia Related to Concomitant Administration of Piperacillin and TazobactamNew England Journal of Medicine, 2003
- Risk factors for invasive aspergillosis in liver transplant recipientsLiver Transplantation, 2002
- Use of Circulating Galactomannan Screening for Early Diagnosis of Invasive Aspergillosis in Allogeneic Stem Cell Transplant RecipientsThe Journal of Infectious Diseases, 2002
- Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosisThe Pediatric Infectious Disease Journal, 1996
- Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996